149 related articles for article (PubMed ID: 16264820)
1. First-line treatment options for patients with metastatic colorectal cancer.
Schilsky RL
Nat Clin Pract Oncol; 2004 Dec; 1(2):70-1. PubMed ID: 16264820
[No Abstract] [Full Text] [Related]
2. First-line chemotherapy with low-dose leucovorin plus 5-fluorouracil (LV/5-FU) for elderly patients with metastatic colorectal cancer.
Yoshimatsu K; Yokomizo H; Fujimoto T; Umehara A; Otani T; Matsumoto A; Osawa G; Shiozawa S; Katsube T; Naritaka Y; Ogawa K
Anticancer Res; 2007; 27(3B):1641-4. PubMed ID: 17595789
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
Giacchetti S; Bjarnason G; Garufi C; Genet D; Iacobelli S; Tampellini M; Smaaland R; Focan C; Coudert B; Humblet Y; Canon JL; Adenis A; Lo Re G; Carvalho C; Schueller J; Anciaux N; Lentz MA; Baron B; Gorlia T; Lévi F;
J Clin Oncol; 2006 Aug; 24(22):3562-9. PubMed ID: 16877722
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy for colorectal cancer.
Maughan TS
Br J Cancer; 2001 Nov; 85(10):1422-4. PubMed ID: 11720422
[No Abstract] [Full Text] [Related]
5. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamaguchi Y; Hasuike N; Yamazaki K; Machida N; Ono H
Jpn J Clin Oncol; 2007 Sep; 37(9):686-91. PubMed ID: 17720736
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
9. [Role of sequential chemotherapy in the treatment of metastatic colorectal cancer].
Tassinari D; Tamburini E; Carloni F; Nicoletti S; Ravaioli A
Recenti Prog Med; 2009 Feb; 100(2):73-9. PubMed ID: 19350798
[TBL] [Abstract][Full Text] [Related]
10. Optimal treatment of metastatic colorectal cancer.
Pessino A; Sobrero A
Expert Rev Anticancer Ther; 2006 May; 6(5):801-12. PubMed ID: 16759170
[TBL] [Abstract][Full Text] [Related]
11. Benefit of FOLFOX to unresectable liver metastases secondary from colorectal carcinoma in an oncologic emergency.
Sugimoto M; Yasuda H; Koda K; Yamazaki M; Tezuka T; Takenoue T; Kosugi C; Higuchi R; Yamamoto S; Watayo Y; Yagawa Y; Suzuki M
Hepatogastroenterology; 2007 Sep; 54(78):1684-8. PubMed ID: 18019695
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
13. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
Efficace F; Innominato PF; Bjarnason G; Coens C; Humblet Y; Tumolo S; Genet D; Tampellini M; Bottomley A; Garufi C; Focan C; Giacchetti S; Lévi F;
J Clin Oncol; 2008 Apr; 26(12):2020-6. PubMed ID: 18421055
[TBL] [Abstract][Full Text] [Related]
14. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study of irinotecan plus infusional fluorouracil/l-leucovorin (FOLFIRI) in patients with fluoropyrimidine-resistant metastatic colorectal cancer].
Moriwaki T; Hyodo I; Nishina T; Kajiwara T; Kataoka J; Hori S; Nasu J; Imamine S; Iguchi H
Gan To Kagaku Ryoho; 2007 Dec; 34(13):2249-53. PubMed ID: 18079624
[TBL] [Abstract][Full Text] [Related]
16. Metastatic colorectal cancer: is surgery necessary?
Schmidt C
J Natl Cancer Inst; 2009 Aug; 101(16):1113-5. PubMed ID: 19671774
[No Abstract] [Full Text] [Related]
17. Another study of how to give fluorouracil?
Saltz LB
J Clin Oncol; 2003 Oct; 21(20):3711-2. PubMed ID: 12963699
[No Abstract] [Full Text] [Related]
18. [Treatment for recurrent colorectal cancer].
Matsui T; Kotake K; Koyama Y
Nihon Rinsho; 2003 Sep; 61 Suppl 7():589-92. PubMed ID: 14574962
[No Abstract] [Full Text] [Related]
19. [Chemotherapy of colorectal cancer. Screening systems--value of special cytostatic drug combinations].
Scheithauer W
Fortschr Med; 1991 Aug; 109(25):504. PubMed ID: 1937338
[No Abstract] [Full Text] [Related]
20. Another effective chemotherapy combination for colorectal cancer.
Oncology (Williston Park); 1988 Nov; 2(11):68. PubMed ID: 3275045
[No Abstract] [Full Text] [Related]
[Next] [New Search]